Computed Tomography (CT)-guided lung biopsy with the superDimension i-Logic System (Covidien)
Record ID 32013000574
English
Authors' recommendations:
The American Cancer Society estimates that lung cancer will be newly diagnosed in 228,190 individuals in the United States in 2013, and that it will lead to an estimated 159,480 deaths. The primary risk factor is tobacco use and measures to reduce smoking are believed to have the greatest potential to reduce lung cancer mortality. However, long-term survival improves with early detection of the disease. To make a diagnosis and distinguish benign from malignant tumors, suspicious lesions must be biopsied. For most patients, this requires a minimally invasive lighted tube to be passed through the airways (fiberoptic bronchoscopy) that enables a biopsy to collect a sample of the abnormal tissue for histopathological examination. However, a number of lesions are beyond the reach of the bronchoscope. Standard diagnostic techniques can be invasive and cause complications.
Details
Project Status:
Completed
Year Published:
2013
URL for published report:
The report may be purchased from: http://www.hayesinc.com/hayes/crd/?crd=3680
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Biopsy, Fine-Needle
- Biopsy, Needle
- Tomography Scanners, X-Ray Computed
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
2013 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.